Molecular target therapy in patients with chronic myelogeneous leukemia *
The introduction of imatinib mesilate（imatinib）, which is a molecule target drug, may lead to a substantial revolution in the management of Philadelphia-positive chronic myelogeneous leukemia（CML）. Imatinib inhibits the binding site for adenosine triphosphate（ATP）to Ablkinase, thus blocking the phosphorylation of tyrosine on substrate protein. Imatinib has shown encouraging results in all phases of CML in comparison with conventional interferon therapy. Now imatinib has replaced interferon as the medicine of the first choice for CML. However, the long-term survival benefits and adverse effects of imatinib treatment are still unknown. In addition, the appearance of CML patients with resistance to imatinib has become a clinical problem recently. This report describes a treatment effect and an adverse effect of molecular target therapy for CML and describes the treatment outcome in our division.(Accepted on December 21，2005)
